Abstract
The online version contains supplementary material available at 10.1007/s43657-021-00026-x.
Highlights
Adrenocortical carcinoma (ACC) is a rare endocrine malignancy with an incidence of 0.7–2 new cases per million per year, and it accounts for 0.2% of all cancer mortalities in the United States (Kostiainen et al 2019)
We aimed to identify prognosis-related Alternative splicing (AS) events (PASEs) using the the Cancer Genome Atlas (TCGA) SpliceSeq dataset and clinicopathological data of patients with ACC by complex bioinformatics and real-world data
3,614 Prognosis-related AS events (PASEs) and 2,261 corresponding genes were identified after matching SpliceSeq sequences and clinical pathological data in TCGA-ACC patients
Summary
Adrenocortical carcinoma (ACC) is a rare endocrine malignancy with an incidence of 0.7–2 new cases per million per year, and it accounts for 0.2% of all cancer mortalities in the United States (Kostiainen et al 2019). Surgery is usually the first and most effective therapeutic strategy for treating patients with ACC. Mitotane is the major medication approved by the United States Food and Drug Administration for ACC treatment for patients with metastasis (Schteingart et al 2005). High-risk patients with ACC can be treated with mitotane alone or in combination with cytotoxic drugs, but these treatments have limited survival benefits (Jasim and Habra 2019). The combination of mitotane and etoposide/doxorubicin/cisplatin (EDP) is the standard treatment in advanced ACC, but its effects in improving survival time is still unsatisfactory (Libe 2015; Tierney et al 2019)
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
